VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment

BACKGROUND: Targeting tumor vasculature is a strategy with great promise in the treatment of many cancers. However, anti-angiogenic reagents that target VEGF/VEGFR2 signaling have met with variable results clinically. Among the possible reasons for this may be heterogeneous expression of the target...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Patten, Steven G, Adamcic, Una, Lacombe, Kristen, Minhas, Kanwal, Skowronski, Karolina, Coomber, Brenda L
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2010
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3009683/
https://ncbi.nlm.nih.gov/pubmed/21159176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-10-683
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares